Synergism between Medihoney and Rifampicin against Methicillin-Resistant Staphylococcus aureus (MRSA)

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Müller, Patrick ^a   Alber, Dagmar G ^a   Turnbull, Lynne ^a   Schlothauer, Ralf C ^b   Carter, Dee A ^c   Whitchurch, Cynthia B ^a   Harry, Elizabeth J ^a  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b Chief Technology Officer   (New Zealand)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MEDIHONEY; METHYLGLYOXAL; NATURAL PRODUCT; RIFAMPICIN; UNCLASSIFIED DRUG;

AGAR DIFFUSION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; DRUG EFFECT; GROWTH INHIBITION; IN VITRO STUDY; LEPTOSPERMUM; LEPTOSPERMUM SCOPARIUM; LIMIT OF DETECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; LEPTOSPERMUM; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PLANT EXTRACTS; RIFAMPIN; RISK; STAPHYLOCOCCAL SKIN INFECTIONS;

EID: 84874575854     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057679     Document Type: Article

References (59)

1. Sen CK, Gordillo GM, Roy S, Kirsner R, Lambert L, et al. (2009) Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair and Regeneration 17: 763-771.
2. Saleem M, Nazir M, Ali MS, Hussain H, Lee YS, et al. (2010) Antimicrobial natural products: an update on future antibiotic drug candidates. Nat Prod Rep 27: 238-254.
3. Dowd S, Sun Y, Secor P, Rhoads D, Wolcott B, et al. (2008) Survey of bacterial diversity in chronic wounds using pyrosequencing, DGGE, and full ribosome shotgun sequencing. BMC microbiology 8: 43.
4. Harbarth S, Hawkey PM, Tenover F, Stefani S, Pantosti A, et al. (2011) Update on screening and clinical diagnosis of meticillin-resistant Staphylococcus aureus (MRSA). International journal of antimicrobial agents 37: 110-117.
5. Fazli M, Bjarnsholt T, Kirketerp-Moller K, Jorgensen B, Andersen AS, et al. (2009) Nonrandom distribution of Pseudomonas aeruginosa and Staphylococcus aureus in chronic wounds. Journal of clinical microbiology 47: 4084.
6. Eliopoulos GM, Cosgrove SE, Carmeli Y, (2003) The impact of antimicrobial resistance on health and economic outcomes. Clinical Infectious Diseases 36: 1433-1437.
7. ECDC E (2009) The bacterial challenge: time to react. Stockholm: European Center for Disease Prevention and Control.
8. Wagner H, Ulrich-Merzenich G, (2009) Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine 16: 97-110.
9. Leibovici L, Paul M, Andreassen S, (2010) Balancing the benefits and costs of antibiotic drugs: the TREAT model. Clinical Microbiology and Infection 16: 1736-1739.
10. Tiwari R, Bharti S, Kaur H, Dikshit R, Hoondal G, (2005) Synergistic antimicrobial activity of tea & antibiotics. Indian Journal of Medical Research 122: 80.
11. Lee J, Ji Y, Lee S, Lee I, (2007) Effect of Saliva miltiorrhiza bunge on antimicrobial activity and resistant gene regulation against methicillin-resistant Staphylococcus aureus (MRSA). Journal of Microbiology Seoul 45: 350.
12. Rahal JJ, (2006) Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clinical infectious diseases 43: S95-S99.
13. Gal K, (1965) Combined antibiotic therapy. Canadian Medical Association Journal 93: 844.
14. Efem S, (1988) Clinical observations on the wound healing properties of honey. British journal of Surgery 75: 679-681.
15. Taormina PJ, Niemira BA, Beuchat LR, (2001) Inhibitory activity of honey against foodborne pathogens as influenced by the presence of hydrogen peroxide and level of antioxidant power. International journal of food microbiology 69: 217-225.
16. Willix D, Molan P, Harfoot C, (1992) A comparison of the sensitivity of wound-infecting species of bacteria to the antibacterial activity of manuka honey and other honey. Journal of Applied Microbiology 73: 388-394.
17. Jenkins R, Burton N, Cooper R, (2011) Effect of manuka honey on the expression of universal stress protein A in meticillin-resistant Staphylococcus aureus. International journal of antimicrobial agents 37: 373-376.
18. Jenkins R, Burton N, Cooper R, (2011) Manuka honey inhibits cell division in methicillin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 66: 2536-2542.
19. Cooper R, Molan P, Harding K, (2002) The sensitivity to honey of gram positive cocci of clinical significance isolated from wounds. Journal of Applied Microbiology 93: 857-863.
20. Blair S, Cokcetin N, Harry E, Carter D, (2009) The unusual antibacterial activity of medical-grade Leptospermum honey: antibacterial spectrum, resistance and transcriptome analysis. European journal of clinical microbiology & infectious diseases 28: 1199-1208.
21. Cooper R, Jenkins L, Henriques AFM, Duggan R, Burton N (2010) Absence of bacterial resistance to medical-grade manuka honey. European journal of clinical microbiology & infectious diseases: 1-5.
22. Mavric E, Wittmann S, Barth G, Henle T, (2008) Identification and quantification of methylglyoxal as the dominant antibacterial constituent of Manuka (Leptospermum scoparium) honeys from New Zealand. Molecular nutrition & food research 52: 483-489.
23. Adams CJ, Boult CH, Deadman BJ, Farr JM, Grainger MNC, et al. (2008) Isolation by HPLC and characterisation of the bioactive fraction of New Zealand manuka (Leptospermum scoparium) honey. Carbohydrate research 343: 651-659.
24. Allen K, Molan P, Reid G, (1991) A survey of the antibacterial activity of some New Zealand honeys. Journal of pharmacy and pharmacology 43: 817-822.
25. Kwakman PHS, te Velde AA, de Boer L, Speijer D, Vandenbroucke-Grauls CMJE, et al. (2010) How honey kills bacteria. The FASEB Journal 24: 2576.
26. Kwakman PHS, Zaat SAJ, (2011) Antibacterial components of honey. IUBMB life 64: 48-55.
27. Villar M, Marimón JM, García-Arenzana JM, Adela G, Ferrándiz MJ, et al. (2011) Epidemiological and molecular aspects of rifampicin-resistant Staphylococcus aureus isolated from wounds, blood and respiratory samples. Journal of Antimicrobial Chemotherapy 66: 997-1000.
28. Zheng Z, Stewart PS, (2002) Penetration of rifampin through Staphylococcus epidermidis biofilms. Antimicrobial agents and chemotherapy 46: 900-903.
29. Eng RHK, Sharon M, Buccini FJ, Cherabin CE, (1985) Differences in ability of cell-wall antibiotics to suppress emergence of rifampicin resistance in Staphyloccocus aureus. Journal of Antimicrobial Chemotherapy 15: 201-207.
30. Iyer S, Jones DH, (2004) Community-acquired methicillin-resistant Staphylococcus aureus skin infection: A retrospective analysis of clinical presentation and treatment of a local outbreak. Journal of the American Academy of Dermatology 50: 854-858.
31. Ribner B, Keusch G, Hanna B, Perloff M, (1976) Combination amphotericin B-rifampin therapy for pulmonary aspergillosis in a leukemic patient. Chest 70: 681-683.
32. Bals M, Filipescǔ S, (1969) The antistaphylococcal activity of Rifampicin. Arzneimittel-Forschung 19: 1285.
33. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, et al. (2001) Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104: 901-912.
34. Feklistov A, Mekler V, Jiang Q, Westblade LF, Irschik H, et al. (2008) Rifamycins do not function by allosteric modulation of binding of Mg2+ to the RNA polymerase active center. Proceedings of the National Academy of Sciences 105: 14820.
35. Aubry-Damon H, Soussy CJ, Courvalin P, (1998) Characterization of mutations in therpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrobial agents and chemotherapy 42: 2590-2594.
36. Wichelhaus TA, Schäfer V, Brade V, Böddinghaus B, (1999) Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy 43: 2813-2816.
37. Jensen K, Lassen H, (1969) Combined treatment with antibacterial chemotherapeutical agents in staphylococcal infections. QJM 38: 91-106.
38. George NM, Cutting KF, (2007) Antibacterial honey (Medihoney™): in-vitro activity against clinical isolates of MRSA, VRE, and other multiresistant gram-negative organisms including Pseudomonas aeruginosa. Wounds 19: 231.
39. Merckoll P, Jonassen TØ, Vad ME, Jeansson SL, Melby KK, (2009) Bacteria, biofilm and honey: a study of the effects of honey on 'planktonic'and biofilm-embedded chronic wound bacteria. Scandinavian journal of infectious diseases 41: 341-347.
40. Windsor S, Pappalardo M, Brooks P, Williams S, Manley-Harris M, (2012) A convenient new analysis of dihydroxyacetone and methylglyoxal applied to Australian Leptospermum honeys. Journal of Pharmacognosy and Phytotherapy 4: 6-11.
41. Braga LC, Leite AAM, Xavier KGS, Takahashi JA, Bemquerer MP, et al. (2005) Synergic interaction between pomegranate extract and antibiotics against Staphylococcus aureus. Canadian journal of microbiology 51: 541-547.
42. Odds F, (2003) Synergy, antagonism, and what the chequerboard puts between them. Journal of Antimicrobial Chemotherapy 52: 1-1.
43. Eliopoulos GM, Moellering Jr RC (1996) Antimicrobial combinations. In: Lorian V, editor. Antibiotics in laboratory medicine. 4 ed. Baltimore, Md: The Williams & Wilkins Co.
44. Jenkins RE, Cooper R (2012) Synergy between oxacillin and manuka honey sensitizes methicillin-resistant Staphylococcus aureus to oxacillin. Journal of Antimicrobial Chemotherapy.
45. Sherlock O, Dolan A, Athman R, Power A, Gethin G, et al. (2010) Comparison of the antimicrobial activity of Ulmo honey from Chile and Manuka honey against methicillin-resistant Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. BMC Complementary and Alternative Medicine 10: 47.
46. Traczewski MM, Goldmann D, Murphy P, (1983) In vitro activity of rifampin in combination with oxacillin against Staphylococcus aureus. Antimicrobial agents and chemotherapy 23: 571-576.
47. Booth I, Ferguson G, Miller S, Li C, Gunasekera B, et al. (2003) Bacterial production of methylglyoxal: a survival strategy or death by misadventure? Biochemical Society Transactions 31: 1406-1408.
48. Schierle CF, De la Garza M, Mustoe TA, Galiano RD, (2009) Staphylococcal biofilms impair wound healing by delaying reepithelialization in a murine cutaneous wound model. Wound Repair and Regeneration 17: 354-359.
49. Jenkins R, Cooper R, (2012) Improving antibiotic activity against wound pathogens with manuka honey in vitro. PLOS ONE 7: e45600.
50. Adams CJ, Manley-Harris M, Molan PC, (2009) The origin of methylglyoxal in New Zealand manuka (Leptospermum scoparium) honey. Carbohydrate research 344: 1050-1053.
51. Molan PC (2008) An explanation of why the MGO level in manuka honey does not show the antibacterial activity.
52. Mukherjee S, Chaki S, Das S, Sen S, Dutta SK, et al. (2011) Distinct synergistic action of piperacillin and methylglyoxal against Pseudomonas aeruginosa. Indian Journal of Experimental Biology 49: 547.
53. Kwakman PHS, te Velde AA, de Boer L, Vandenbroucke-Grauls CMJE, Zaat SAJ, (2011) Two major medicinal honeys have different mechanisms of bactericidal activity. PLoS One 6: e17709.
54. Hemaiswarya S, Kruthiventi AK, Doble M, (2008) Synergism between natural products and antibiotics against infectious diseases. Phytomedicine 15: 639-652.
55. Shiota S, Shimizu M, Sugiyama J, Morita Y, Mizushima T, et al. (2004) Mechanisms of action of corilagin and tellimagrandin I that remarkably potentiate the activity of beta-lactams against methicillin-resistant Staphylococcus aureus. Microbiology and immunology 48: 67.
56. Lewis K, Ausubel FM, (2007) Prospects for plant-derived antibacterials. Nature 200: 6.
57. Jabar MA, Al-Mossawi A (2010) Susceptibility of some multiple resistant bacteria to garlic extract. African Journal of Biotechnology 6.
58. Ankri S, Mirelman D, (1999) Antimicrobial properties of allicin from garlic. Microbes and infection 1: 125-129.
59. Cooper R, Jenkins L, Henriques AFM, Duggan R, Burton N, (2010) Absence of bacterial resistance to medical-grade manuka honey. European journal of clinical microbiology & infectious diseases 29: 1237-1241.